NKGN(Delisted)
NKGen Biotech·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 0
Bearish signal 1
Low Cash Short-term Debt Ratio
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About NKGN
Nkgen Biotech, Inc.
A clinical-stage biotechnology company focused on autologous, allogeneic and CAR-NK natural killer cell therapies
3001 Daimler Street, Santa Ana, CA, 92705
--
NKGen Biotech, Inc., is a Delaware-based company. The company is a biotechnology company that develops cell therapies for neurodegenerative and tumor diseases based on activated NK cells. NK cells are part of the human innate immune response system and can selectively recognize and destroy abnormal or diseased cells. The Company's product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM cells that show higher activity compared to the starting population of NK cells, based on in vitro experimental results conducted by NKMAX, defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be mass-produced and cryopreserved while maintaining high levels of cytotoxicity and activating receptor expression after thawing and recombination.
Company Financials
EPS
NKGN has released its 2023 Q3 earnings. EPS was reported at -2.48, versus the expected 0, missing expectations. The chart below visualizes how NKGN has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
No Data
You can ask Aime
No Data
